☆ 4.6 Letter

Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)

Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata

Brett King et al.

Summary: This study assessed the safety and efficacy of CTP-543 in patients with chronic, moderate-to-severe AA. The results showed a significant reduction in the severity of AA in patients treated with CTP-543. However, further studies are needed to confirm its safety and efficacy due to the small sample size.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study

Andrea Chiricozzi et al.

Summary: This study assessed the efficacy and safety of upadacitinib in treating patients with atopic dermatitis in a real-world setting. The results showed that upadacitinib significantly improved disease severity scores and quality of life in patients who were unresponsive to dupilumab.

DRUGS IN R&D (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis

Laura Calabrese et al.

Summary: Atopic dermatitis (AD) is the most common inflammatory skin disorder with limited therapeutic options. The JAK/STAT signaling pathway plays a significant role in the pathogenesis of AD, and JAK inhibitors have shown promise as effective drugs for treating AD.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2022)

添加到收藏夹

Article Dermatology

Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata

Brett King et al.

Summary: The study aimed to evaluate the safety and efficacy of CTP-543 in patients with AA. The results showed a significant reduction in the severity of AA in patients receiving 8mg and 12mg of CTP-543, demonstrating promising treatment effects.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Autoimmune diseases in adults with atopic dermatitis

Yuki M. F. Andersen et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)

添加到收藏夹

Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study

相关参考文献

Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata

Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study

Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis

Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata

Autoimmune diseases in adults with atopic dermatitis

导出引文

分享论文